Capece M L, Efange S M, Lydic R
Department of Anesthesia, Pennsylvania State University, College of Medicine, Hershey 17033, USA.
Neuroreport. 1997 Jan 20;8(2):481-4. doi: 10.1097/00001756-199701200-00021.
The vesamicol-like compound (+/-)-4-aminobenzovesamicol (ABV) non-competitively inhibits vesicular packaging of acetylcholine (ACh) in presynaptic terminals. This study tested the hypothesis that microinjection of ABV into the medial pontine reticular formation (mPRF) of intact, unanesthetized cats would inhibit rapid eye movement (REM) sleep. Microinjection of ABV alone or before administration of the acetylcholinesterase inhibitor neostigmine was used to evaluate the effects of ABV on natural REM sleep and on the neostigmine-induced REM sleep-like state. ABV decreased (24.8%) REM sleep and significantly reduced (33.6%) the neostigmine-induced REM sleep-like state. The results show for the first time that REM sleep generation can be disrupted by blocking a synaptic vesicle protein that modulates ACh transport in localized regions of the mPRF.
类维生霉素化合物(±)-4-氨基苯维生霉素(ABV)非竞争性抑制突触前终末中乙酰胆碱(ACh)的囊泡包装。本研究检验了以下假说:向完整、未麻醉猫的脑桥内侧网状结构(mPRF)微量注射ABV会抑制快速眼动(REM)睡眠。单独微量注射ABV或在给予乙酰胆碱酯酶抑制剂新斯的明之前进行微量注射,以评估ABV对自然REM睡眠以及新斯的明诱导的REM睡眠样状态的影响。ABV使REM睡眠减少了24.8%,并显著降低了新斯的明诱导的REM睡眠样状态33.6%。结果首次表明,通过阻断一种调节mPRF局部区域ACh转运的突触囊泡蛋白,可扰乱REM睡眠的产生。